Register for our free email digests:
Division of MediciNova Inc.
Latest From Anchen Pharmaceuticals Inc.
The generics maker is expanding its portfolio of reformulations through the acquisition of privately-held JHP in a deal worth $490 million, expected to close in short order.
Tiny Sucampo is betting that its new drug Rescula can make inroads in a heavily generic market because of its clean safety profile and efficacy, but at $99 per 30-day supply WAC, it faces significant headwinds.
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Following the clinical trial failure of cancer candidate saridegib, Infinity takes back partnered assets from Purdue and plans to go it alone in the PI3K space.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- MediciNova Inc.
- Senior Management
Andrew Sauter, CEO
Kirk W Johnson, PhD, VP, R&D
- Contact Info
Phone: (510) 748-7150
1301 Harbor Bay Pkwy
Alameda, CA 94502
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.